Also, in a mouse proof-of-concept study, therapeutic responses to PD-1 blockade were assessed based on levels of PD-1 expression (PD-1hi and PD-1lo) by T cells and both myeloid and T cell PD-L1 expression (PD-L1hi) in the tumor microenvironment (130). This evidence concerns the gene CD274 and neoplasm.